L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés


Antibodies for medicine (MI-mAbs (ex: CIMTECH))


Action : Démonstrateurs


N° de convention : 11-DPBS-0002

Informations générales

  • Référence projet : 11-DPBS-0002
  • RST : Francois ROMAGNé
  • Etablissement Coordinateur : Université d'Aix-Marseille
  • Région du projet : Provence-Alpes-Côte d'Azur
  • Discipline : 5 - Bio Med
  • Aide allouée : 19 000 000 €
  • Date de début du projet : 01/09/2012
  • Date de fin du projet : 31/12/2019
  • Site web du projet : www.mimabs.org
  • Mots clés : monoclonal antibody; immunotherapy; antibody engineering; therapeutic target validation

Résumé du projet

  MI-mAbs, a consortium led by Aix-Marseille University, is an immunotechnology platform, using systemic biology and monoclonal antibody generation to validate new potential therapeutic targets coming from public or private research, in the field of immunology, cancer immunotherapy and inflammation. MI-mAbs is structured to attract key academic and private players in the field of immunotherapy to speed up the transfer of academic research concept to biotech or pharma development. For a given target, MI-mAbs generates a panel of recombinant mAbs and determines in vitro on human samples and in vivo in relevant mice models the existence of a therapeutic window, allowing biotech and pharma to pursue costly developments on best candidates.   The positioning of MI-mAbs is unique for the qualification of mAb candidates due to the complementary expertise of the different founder partners. Innate pharma brings different technologies for the engineering of mAbs, Sanofi brings its experience in late development and access to some of its technical platforms. CIML facilitates access to expertise and models in immunology, and IPC and CRCM their expertise in cancer and access to cancer patient samples. MI-mAbs has also access to CIPHE platform for the generation of innovative preclinical models based on genetically engineered mice, and extensive immune monitoring capabilities. The different partners are represented in a steering committee, ensuring the governance of the structure.   The structure is now fully operational with 22 persons recruited in different functional units: mAb generation, mAb engineering, pharmacology, immunohistochemistry and bioinformatics. Staff is currently hosted by partner labs, but will move in a dedicated building in March 2017.   Characterization and validation of different targets in the immuno-oncology field are currently ongoing, with academic and industrial partners. In 2016, research contracts amounted 1060 k€ (540 k€ in 2014), mostly with industry.  

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)